Aerpio Therapeutics, Inc.

The Procter Gamble Company

Akebia Therapeutics, Inc.

Joseph H Gardner

Robert A Shalwitz

Thomas L Cupps

James Berger Camden

David Thomas Stanton

Gerald B Kasting

Joel I Shulman

Thomas W Gibson

Richard S Echler

John M Janusz

Brian Lee Buckwalter

William Lee Seibel

Shengde Wu

Charlotte Suzanne Hartman

Isaiah Shalwitz

Elizabeth F Berman

Akshay Buch

Charlotte Hartman

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and methods for treating anemia

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1&#x3b1;), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

Prolyl hydroxylase inhibitors

Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1&#x3b1;) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1&#x3b1; prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1&#x3b1;.

Methods for increasing the stabilization of hypoxia inducible factor-&#x3b1;

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2&#x3b1;) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer.

Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis.

Compositions and methods for treating colitis

A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, is disclosed. This same composition is can be used to treat viral infections, particularly HIV. The composition comprises from about 10 mg to about 10000 mg of a carbamic acid ester derivative of the formula:

Viral treatment

A pharmaceutical composition is disclosed to treat viral infections, particularly HIV and hepatitis, as well as to treat fungal infections of the genus,or,. The composition comprises from about 10 mg to about 6000 mg of a 2-thienyl-imidazolo &lsqb;4,5&rsqb;pyridine of the formula:

The present invention relates to beta-aminoethyl-substituted phenyl compounds, especially beta-aminoethoxy-substituted phenyl compounds. The present invention also relates to pharmaceutical compositions comprising a safe and effective amount of a compound of the present invention and a pharmaceutically-acceptable carrier. The present invention further relates to methods for producing analgesia and reducing inflammation, in humans and lower animals, by administering the compounds or compositions of the present invention. In addition, the present invention relates to methods for making compounds of the present invention and intermediates useful in these synthesis methods.

Novel compounds, pharmaceutical compositions, and methods for treating

The subject invention involves halogenated amino acid derivatives useful as antimicrobial agents having the structure: ##STR1## wherein --R is hydrogen or 2-aminoethyl; --R' is hydroxy, alkoxy, aryloxy, or an amino acid residue bonded at the amino nitrogen; --R' is hydrogen or an amino acid residue bonded at the carbonyl carbon; --X is halogen; and --Y is hydrogen or halogen.

Growing community of inventors

Cincinnati, OH, United States of America

Joseph H Gardner